Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 800,000 shares at $9.53 ($7.5M) on 2025-05-27, disclosed to the SEC on 2025-05-29.
Scheduled sale ($7.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.53 | 32,432 | $309K | 4.1% |
| 2 | $9.53 | 32,432 | $309K | 4.1% |
| 3 | $9.30 | 162,704 | $1.5M | 20.3% |
| 4 | $9.30 | 162,704 | $1.5M | 20.3% |
| 5 | $9.33 | 204,864 | $1.9M | 25.6% |
| 6 | $9.33 | 204,864 |
| $1.9M |
| 25.6% |
| Total | $9.33 avg | 800,000 | $7.5M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |
| VRNA | SELL | 2024-12-06 | $8.5M | — | Filing → |